A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Participants will be followed for 5.5 years post-transplant for long-term safety via an
annual telephone contact.

Inclusion Criteria:

- Participant is a CMV-seropositive HCT recipient

- Participant is planned to undergo either of the following:

- Sibling Donor Transplant

- Unrelated Donor Transplant

- Participant has one of the following underlying diseases:

- Acute myeloid leukemia (AML)

- Acute lymphoblastic leukemia (ALL)

- Acute undifferentiated leukemia (AUL)

- Acute biphenotypic leukemia

- Chronic myelogenous leukemia (CML)

- Chronic lymphocytic leukemia (CLL).

- A defined myelodysplastic syndrome(s) (MDS)

- Primary or secondary myelofibrosis

- Lymphoma (including Hodgkin's)

Exclusion Criteria:

- Participant has active CMV disease or infection or has received treatment for active
CMV disease or infection within 3 months (90 days) prior to transplant

- Participant has a modified hematopoietic cell transplant comorbidity index (HCT-CI)
score ≥ 4

- Participant has received a prior HCT and has residual Chronic Graft-versus-host
Disease (cGVHD)

- Participant who is scheduled to have a cord blood transplant or a haploidentical
transplant

- Participant has a platelet count of less than 50,000 mm3 within 3 days prior to
randomization (platelet transfusions are allowed)

- Participant has aplastic anemia or multiple myeloma